Polyploid AAV Capsid Assembly for Immune-Evasive Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV vectors face challenges such as species-specific differences in transgene expression, low infectivity requiring high doses, and neutralizing antibody responses, which hinder effective gene therapy applications.
Innovation Solution
Development of rational polyploid AAV vectors with mixed capsid shells from multiple AAV serotypes, allowing for higher transduction efficiency and neutralizing antibody evasion, achieved through controlled assembly of viral proteins VP1, VP2, and VP3 from different serotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high doses of AAV vectors are used to overcome low infectivity, then transduction efficiency improves, but immune response and neutralizing antibody formation worsen
Solution Approach 1:
The patent applies composite materials by creating hybrid AAV capsids that combine structural proteins (VP1, VP2, VP3) from different AAV serotypes. This composite capsid structure merges the high infectivity characteristics of one serotype with the immune evasion capabilities of another, achieving both high transduction efficiency and reduced neutralizing antibody response simultaneously
Solution Approach 2:
The patent implements local quality by selectively incorporating specific capsid proteins from different serotypes into the hybrid capsid structure. Each serotype's VP proteins contribute specific local properties: one serotype provides high infectivity through its VP proteins, while another serotype provides immune evasion characteristics, creating a capsid with spatially differentiated functional properties
2Reliability
If AAV vectors are used for gene delivery, then therapeutic gene expression is achieved, but species-specific differences in transduction efficiency create inconsistency
Solution Approach 1:
The patent applies universality by designing hybrid AAV capsids that combine the broad tissue tropism and high infectivity of one serotype with the enhanced transduction capabilities across different species from another serotype. This multi-functional capsid structure achieves reliable therapeutic gene expression while reducing species-specific variability in transduction efficiency
3Productivity
If multiple AAV serotypes are combined to create polyploid vectors, then transduction capabilities are enhanced, but vector production complexity increases
Solution Approach 1:
The patent implements merging by co-expressing multiple serotype-specific capsid protein genes (VP1, VP2, VP3 from different serotypes) in a single production system. The hybrid capsids are assembled through natural viral assembly processes, combining the transduction advantages of multiple serotypes while using a unified production platform that reduces overall complexity compared to producing separate vector populations
Data Source
AI summary
The present invention provides a polyploid adeno-associated virus (AAV) capsid, wherein the capsid comprises capsid protein VP1, wherein said capsid protein VP1 is from one or more than one first AAV serotype, wherein said capsid protein VP2 is from one or more than one first AAV serotype and capsid protein VP3, wherein said capsid protein VP3 is from one or more than one second AAV serotype and wherein at least one of said first AAV serotype is different from at least one of said second AAV serotype and is different from at least one of said third AAV serotype, in any combination.